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Abstract: Recent increase in human lifespan has shifted the spectrum of aging-related disorders to an unprecedented up-
surge in cardiovascular diseases, especially calcific aortic valve stenosis, which has an 80% risk of progression to heart 
failure and death. A current therapeutic option for calcified valves is surgical replacement, which provides only temporary 
relief. Recent progress in cardiovascular research has suggested that arterial and valve calcification are the result of an ac-
tive process of osteogenic differentiation, induced by a pro-atherogenic inflammatory response. At molecular level, the 
calcification process is regulated by a network of signaling pathways, including Notch, Wnt and TGFbeta/BMP pathways, 
which control the master regulator of osteogenesis Cbfa1/Runx2. Genetic and in vitro studies have implicated Notch sig-
naling in the regulation of macrophage activation and cardiovascular calcification. Individuals with inactivating Notch1 
mutations have a high rate of cardiovascular disorders, including valve stenosis and calcification. This article reviews re-
cent progress in the mechanism of cardiovascular calcification and discusses potential molecular mechanisms involved, 
focusing on Notch receptors. We propose a calcification model where extreme increases in vascular wall cell density due 
to inflammation-induced cell proliferation can trigger an osteogenic differentiation program mediated by Notch receptors.  
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CARDIOVASCULAR CALCIFICATION IS AN   
INFLAMMATORY DISEASE 
  Cardiovascular disorders are the most prevalent cause of 
death in the US. Atherosclerosis, the most frequent cardio-
vascular disorder, is the result of a gradual accumulation of 
atheromatous plaques in the arterial wall. The prognostic is 
especially unfavorable when such plaques accumulate in the 
coronary arteries, cerebral arteries or aorta, where they can 
lead to often-fatal cardiovascular accidents such as stroke, 
heart attacks or heart failure. Plaque calcification causes an 
increased risk of rupture due to mechanical stress at the in-
terface between the rigid calcified plaque and neighboring 
soft “unstable” atheroma [1-3]. In addition, microcalcifica-
tion in the thin fibrous cap may cause microfractures leading 
to plaque rupture, thrombosis and acute cardiovascular 
events [4]. Furthermore, calcification impacts clinical out-
come not only by complicating atherosclerosis but also by 
impairing the movement of aortic valve leaflets, increasing 
arterial stiffness or causing plaque fracture during angio-
plasty.  
  A number of defects and/or polymorphisms of proteins 
involved in the fat transport pathways, notably the apolipo-
proteins and the LDL receptor, markedly contribute to in-
creased atheroma and calcification risks. Defects in these 
proteins are associated with hyperlipoproteinemia or hyper-
cholesterolemia, have a frequency of 1:500 to 1:1000 in the 
general population and are characterized by a significant 
increase in coronary heart disease susceptibility. In the past 
decade however, preclinical and clinical studies have pro-
posed that active osteogenic mechanisms contribute to arte-
rial and valvular calcification, replacing the traditional view 
of passive lipid accumulation and cellular degeneration. This  
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idea has only recently started to be accepted and investi-
gated, although the underlying information has been avail-
able for several decades. Early in vitro studies proposed that 
calcification is the result of an inflammatory process induced 
by LDL oxidation and uptake by macrophages, which be-
come foam cells [5]. This model was supported by in vivo 
results showing that anti- inflammatory drugs such as statins 
may also inhibit osteogenic pathways in myofibroblasts of 
hypercholesterolemic rabbits [6-8]. Recent advances in sig-
nal transduction have expanded this model, networking to-
gether a number of signaling pathways previously regarded 
as unrelated. A simplified diagram of the processes involved 
in calcification, associated with corresponding molecular 
signaling mechanisms, is shown in Fig. (1). 
  Our recent studies have used innovative functional imag-
ing strategies to monitor valvular and atherosclerotic lesion 
initiation and progression. These have provided robust evi-
dence that inflammation correlates with osteoblastic activity 
preceding the development of advanced calcification,  sug-
gesting that inflammation triggers osteoblastic activity of 
myofibroblast-like cells thus promoting calcification (Fig. 
(2)) [9-12]. Furthermore, we also demonstrated that statin 
treatment of early-stage atherosclerosis reduced inflamma-
tion and osteogenic activity in parallel, supporting the con-
cept that early pharmacological modification of proinflam-
matory processes retards the progression of cardiovascular 
calcification [12].  
  While intimal calcification is connected to the atheroscle-
rotic process and lipid processing, type II diabetes and 
chronic kidney disease often lead to the calcification of the 
medial layer of the vascular wall. This process is connected 
to elastin degradation by proteolytic enzymes rather than to 
lipid transport and oxidation and can take place independ-
ently of atherosclerosis. Elastin degradation peptides have 
pro-inflammatory properties similar to the oxidized choles-
terol and can act as macrophage chemoattractants [13] (Fig. 
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(Williams-Beuren syndrome, pseudoxanthoma elasticum, 
Marfan syndrome) have been associated with fibroblast and 
smooth muscle cell proliferation, cardiovascular calcification 
as well as with a chronic inflammatory state. Although hav-
ing different etiologies, both intimal and medial calcification 
involve the activation of a pro-inflammatory mechanism and 
the initiation of smooth muscle cell proliferation, which 
likely continue through similar calcification paradigms. A 
very similar thickening and calcification process induced by 
inflammation affects heart valves [14, 15], leading to valve 
stenosis, characterized by decreased valve elasticity and in-
complete closing/opening, and to calcific aortic valve disease 
that currently has no therapeutic options other than surgical 
valve replacement. 
  This review discusses recent developments in unraveling 
the cellular and molecular aspects of cardiovascular calcifi-
cation as a key process in cardiovascular disease, focusing 
on the Notch pro-inflammatory pathway as a candidate target 
for pharmacological therapy with the potential to replace 
surgical solutions. 
CELLULAR MECHANISMS OF CARDIOVASCULAR 
CALCIFICATION 
  The elucidation of the mechanisms of cardiovascular 
calcification is an ongoing process, complicated by the fact 
that even the origin of calcified cells in cardiovascular le-
sions is yet an unresolved question. Osteoblasts may arise 
either through vascular smooth muscle cells (VSMC) de-
differentiation and proliferation [16], from circulating bone-
marrow-derived stem cells in the blood [17, 18] or from mul-
tipotent calcifying vascular cells resident in the vascular wall 
that have the potential to differentiate into VSMC, os-
teoblasts and chondrocytes [19]. All these mechanisms are 
likely to contribute to some degree, although the repertoire
 of 
cell lineages present in lesions and their capacity for self-
renewal suggests that mesenchymal stem cells, either resi-
dent or bone-marrow-derived, have a significant contribu-
tion. An in situ source of mesenchymal stem cells can be 
also provided through endothelial-mesenchymal transition, a 
mechanism that occurs in cardiac valves throughout embry-
onic development and disease [20, 21]. Establishing the trig-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Diagram of inflammation-induced osteogenic differentiation. Changes in cellular phenotypes (open arrows) are shown in an inte-
grated network with overlapping regulatory arrays of signal transduction (solid arrows), which form signaling hubs specific for each cell 
type. Major signaling pathways (Wnt, TGF-beta, BMP, Runx2-ALP) that interact with Notch are shown in boxes and major inflammatory 
molecules (NO, TNF-alpha, NFkappaB, HIF1) are in bold. Inflammation, initiated by fat accumulation, elastin degradation or pathogens, 
induces the activation and proliferation of macrophages. Activated macrophages interact with, and induce the proliferation of neighboring 
vascular smooth muscle (VSMCs) cells or resident stem cells (MSCs) through secreted inflammatory molecules as well as direct contact via 
Notch receptors and ligands. The balance between Notch and Wnt pathways, with regulatory contributions from inflammatory molecules, 
TGF-beta and bone morphogenetic proteins (BMPs), controls the proliferation/ differentiation of VSMCs or MSCs. High cell density gener-
ated by initial proliferative phase can tip the balance towards activation of Runx2/ALP and osteogenic differentiation. 150    Current Cardiology Reviews, 2008, Vol. 4, No. 3  Rusanescu et al. 
ger, origin and mechanism of osteoblast and VSMC prolif-
eration are important steps in elucidating the sequence of 
cardiovascular calcification. However, the in vivo identifica-
tion of mesenchymal stem cells as osteoblast precursors has 
been a notoriously difficult task due to their very flexible 
phenotypes. Although a large number of cellular markers 
have been used to identify mesenchymal stem cells, such as 
Stro-1 [22], CD105, SB-10, these are also expressed in some 
cells of mesenchymal origin and therefore cannot unequivo-
cally identify stem cells to determine their location or fre-
quency. The only accepted method to establish the mesen-
chymal stem cell phenotype is to demonstrate their pluripo-
tency and regeneration over a large number of cell divisions. 
An indirect method used to infer the presence of mesenchy-
mal stem cells was to demonstrate that allograft blood ves-
sels contain in the neointima surrounding graft lesions 
smooth muscle cells derived from the host, not from the do-
nor [17, 18].  
  Similarly to the origin of osteoblast and smooth muscle 
cell precursors in the neointima, the mechanism by which the 
inflammatory process triggers the proliferation of these pre-
cursors remains unclear as well. Macrophages can induce 
osteogenic differentiation and calcification both through di-
rect cell contact with precursor cells or by releasing signaling 
molecules such as 1,25-dihydroxyvitamin D (calcitriol) (Fig. 
(1)). This hormone promotes VSMC calcium influx and cal-
cification by interacting with the Wnt pathway [23] at the 
same time it promotes osteoclast and osteoblast activation 
and bone remodeling. Macrophages can also release pro-
inflammatory molecules such as TNF-alpha (see below). 
Another possibility is that direct intercellular contact be-
tween activated macrophages and osteoblast precursors may 
also activate an osteogenic program by juxtacrine signaling, 
for example through Notch-mediated interactions (Fig. (1)).  
  Blood vessels need to maintain their ability to respond to 
injury by repairing damaged blood vessels and sprouting 
new ones, therefore cells involved in this process such as 
VSMC and endothelial cells are not terminally differentiated 
and retain some ability to respond to inflammatory signals by 
triggering cell proliferation. In case of inflammatory signals 
triggered by oxidized LDL, VSMC accumulate in the neoin-
tima instead of extending new blood vessels. This dramatic 
increase in cell density and intercellular contact is likely to 
activate signaling pathways that are normally quiescent, in-
cluding the proliferation of any resident mesenchymal stem 
cells [24]. Although the role of mesenchymal stem cells in 
cardiovascular calcification is still under debate, they have 
been frequently used as a model for calcification due to their 
ability to differentiate into osteoblasts and reproduce os-
teoblast calcification. We find that during cultured mesen-
chymal stem cell calcification, highest cell density areas are 
the first to express alkaline phosphatase (ALP), a typical 
early calcification marker, then form calcified nodules simi-
lar to in vivo cardiovascular calcification
. This suggests that 
excessive neo-intimal proliferation of VSMC associated with 
arterial stenosis may similarly initiate osteogenic trans-
differentiation pathways in vivo through mechanisms dis-
cussed below, which may involve an abnormal activation of 
Notch receptors or integrins. In turn, these receptors can fur-
ther over-stimulate VSMC proliferation in a positive feed-
back loop. In parallel, Notch ligand Jag1 may reduce control 
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Fig. (2). Osteogenesis associates with inflammation in early-stage atherosclerosis. A, Sequential intravital fluorescence microscopy of ApoE 
KO mouse carotid atherosclerotic plaques. ApoE KO mice fed a high-cholesterol diet were imaged in vivo at 20 weeks old, using multichan-
nel laser scanning fluorescence microscopy for simultaneous visualization of osteogenesis (750 nm, red) and inflammation (680 nm, green). 
Mice were then randomized to continue with high-cholesterol diet with the addition or absence of statin for an additional 10 weeks. B, Quan-
tification of inflammation and osteogenesis shown in Fig. 2A, demonstrating that statin treatment reduced by more than 50% areas of both 
inflammation and calcification at 30 weeks. Notch Signaling in Cardiovascular Disease and Calcification  Current Cardiology Reviews, 2008, Vol. 4, No. 3    151 
over cell proliferation by overriding cell contact inhibition, 
contributing to an additional increase in cell density [68]. 
  A concurrent mechanism of calcification following the 
proliferation of a large number of smooth muscle cells and 
reduced nutrient and oxygen access to cells due to tighter 
cellular packing may be mediated by hypoxia and nutrient 
deprivation. This can explain why calcification nodules usu-
ally appear inside the neointima, in highly proliferative ar-
eas, and then extend towards the arterial lumen [21]. In fact 
“high-risk” plaques are primarily characterized by high lev-
els of inflammation, not by the magnitude of arterial occlu-
sion [25]. Hypoxia can activate signaling pathways similar to 
those involved in inflammation, particularly the expression 
of hypoxia-inducible factor (HIF-1, Fig. (1)), a transcription 
factor that promotes cell survival in hypoxic conditions typi-
cally associated with accelerated cell proliferation, for ex-
ample in cancer, atheromas or proliferating stem cells (re-
viewed in [26]). HIF-1 plays a central role in the inflamma-
tory response associated with hypoxia and macrophage inva-
sion, in the angiogenesis induced to offset the effects of hy-
poxia [27] and in osteogenesis [28], all of which are con-
spicuously present in atheromas. In addition, HIF-1 binds to 
Notch directly and acts as a co-activator for CSL-mediated 
transcription [29], providing a direct link between inflamma-
tion, Notch signaling and calcification (Fig. (3)).  
SIGNALING MECHANISMS IN CARDIOVASCULAR 
CALCIFICATION 
  The list of proinflammatory factors that regulate os-
teogenic differentiation
 of vascular cells is rapidly growing 
and includes:
 osteopontin, BMPs, Msx-2, oxidized
 lipopro-
teins, RANKL, PTH, matrix GLA protein, fibrillin, pyro-
phosphate, tumor necrosis factor-alpha,
 oxysterols, osteopro-
tegerin, insulin-like growth factor, interleukins, 1,25-di-
hydroxyvitamin D,
  transforming growth factor-beta, estra-
diol, decorin, fetuin,
 and many others. Following the initial 
cardiovascular injury and inflammation, which may be 
caused by a number of factors such as high blood choles-
terol, infections or genetic disorders, calcification likely pro-
ceeds through a unique molecular mechanism that involves 
the concerted action of a complex signaling network which is 
highly similar to normal skeletal bone development. 
  One signaling pathway directly connected to the lipid 
transport system with a well-established role in osteoblast 
differentiation and calcification is the Wnt pathway (Fig. 
(1)). Wnt signaling includes LDL receptor related proteins 
Lrp5/6, which are co-receptors for Wnt binding but can also 
bind ApoE [30]. Therefore ApoE downregulation has a two-
fold effect on cardiovascular calcification: it results in re-
duced lipid clearance from the blood, thereby enhancing 
cholesterol deposits in blood vessels, but also eliminates the 
competition for Wnt receptors Lrp5 and Lrp6, effectively 
resulting in an activation of the Wnt pathway. The key role 
of Wnt as an inducer of osteoblast differentiation and calcifi-
cation is mediated by beta-catenin, which induces the ex-
pression of Runx2/Cbfa1 [31], considered a master regulator 
of osteogenesis [32]. Runx2/Cbfa1 knockout mice die soon 
after birth and show complete absence of ossification. 
Runx2/Cbfa1 initiates a sequence of calcification regulators 
such as osterix (Osx) [33] , Msx (homeobox-7) [34, 35]and 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Simplified diagram of Notch signaling. Ligand binding to Notch receptors induces sequential receptor cleavage on the extracellular 
and intracellular sides of the membrane by TACE/ADAM and -secretase/presenilin proteases. The Notch intracellular domain (NICD) mi-
grates to the nucleus and acts as a transcription regulator for cardiovascular/osteogenic or neuronal differentiation pathways. Classical Notch 
ligands induce signaling pathways that play a role in cardiovascular development and disease, including calcification, through CSL, 
HES/Hey and Runx2-regulated transcription. Notch glycosylation by Fringe favors binding of Delta-like ligands and inhibits binding of Jag-
ged ligands. Atypical Notch ligands are involved in neuronal development and disease through Deltex-regulated transcription. The two 
pathways are mutually exclusive through reciprocal negative feedbacks. Proteins with a known role in cardiovascular development are 
shown underlined. Proteins with known roles in cardiovascular calcification are shown italics. 152    Current Cardiology Reviews, 2008, Vol. 4, No. 3  Rusanescu et al. 
alkaline phosphatase (ALP), which are early markers of cal-
cification, and osteocalcin, a marker of osteoblast differentia-
tion [32, 36] (Fig. (1)). Wnt implication in calcification is 
part of a larger signaling network that also includes BMP 
[37], TGFbeta, Notch [38] and Hedgehog. These pathways 
interact with each other at multiple levels that are just begin-
ning to be understood.  
  While Wnt signaling is thought to promote osteoblast 
differentiation and calcification, Notch is known to promote 
cell proliferation and activation. Wnt and Notch cellular sig-
nals complement each other in an oscillating network of sig-
nals associated with a segmentation clock that regulates em-
bryonic somite development [39]. The two pathways may 
recapitulate a similar process in the adult cardiovascular sys-
tem when triggered by injury signals that induce quiescent 
adult stem cells, VSMC or valvular myofibroblasts first to 
proliferate and then differentiate into cells necessary for tis-
sue repair. Wnt and Notch pathways interact at several levels 
through positive and negative feedbacks [40]. Wnt induces 
the expression of NUMB, a Notch inhibitor that promotes 
cell differentiation, but also the expression of Jag1, an acti-
vating ligand of Notch (Fig. (1)). In turn, Notch signaling 
induces the expression of Dkk2 (Dickkopf), a Wnt signaling 
inhibitor thought to have osteoclastogenic and tumor sup-
pressor properties [41, 42]. Hey1, another Notch target, is 
thought to inhibit osteoblast differentiation by suppressing 
Runx2/Cbfa1-mediated transcription [38]. The Notch path-
way has been extensively studied in conjunction with its role 
in cell fate determination in the nervous system [43], but 
only recently has the picture of Notch implication in cardio-
vascular calcification started to emerge. The recent discovery 
that Notch1 inactivating mutations lead to severe heart dis-
orders, including valve defects and calcification [44], has 
amplified research efforts in this direction.  
NOTCH SIGNALING 
  Notch signaling is a complex juxtacrine signaling mecha-
nism initiated by the interaction of Notch transmembrane 
receptors (Notch1-4) with their ligands, which are also trans-
membrane proteins (Fig. (3)). Notch ligands include “classi-
cal” ligands Jagged – Jag1 and Jag2 - and Delta-like - DLL1, 
DLL3 and DLL4 - as well as several atypical ligands DNER 
[45], F3/Contactin1, NB-3/Contactin6 [46] and Delta-like 1 
homologue (Dlk1). Notch receptors and classical ligands 
have one DSL and numerous EGF-like domains present in 
their extracellular region, while atypical ligand Dlk1 only 
contains 6 EGF-like repeats and acts as a negative regulator 
by competing against classical Notch ligands [47]. The dif-
ferent types of ligands initiate different signaling pathways 
for Notch receptors summarized in Fig. (3). Notch receptor 
selectivity for either DLL or Jag ligands is regulated through 
glycosylation by Fringe glycosyltransferases [48]. Binding 
of ligands on “sending cell” surface to Notch receptors lo-
cated in “receiving cell” membrane results in sequential 
cleavage of Notch receptors on the extracellular and intracel-
lular sides of cell membrane (designated as S2 and S3)   
by the TACE/ADAM family of metalloproteases and the 
gamma-secretase complex, respectively. Receptor cleavage 
releases the Notch intracellular domain (NICD), which trans-
locates to the nucleus and converts the CSL transcriptional 
repressor into a transcriptional activator, in complex with co-
activators Mastermind-like (Maml) and p300 proteins. 
Notch/ CSL- dependent transcription results in the expres-
sion of hairy/enhancer of split (HES1-HES7) and HES-
related (Hey1-2 and HeyL) genes, which are members of the 
bHLH Orange family of transcriptional repressors, thus in-
hibiting a number of genes.  
  Transgenic mouse models and human genetic disorders 
suggest that the four Notch receptors and their ligands have 
different functions. Logically, they should then be expected 
to induce different HES/Hey transcription patterns, since 
different HES/Hey isoforms appear to have vastly different 
roles in cellular specification. For example HES3 is selec-
tively expressed in the cerebellum, HES5 is strongly upregu-
lated in the embryo around E10 and Hey2 is preferentially 
expressed in the heart. It is also important to note that not all 
hairy/E(spl) family members act in the same direction. In 
some cases, hairy/E(spl) family members may even have 
opposing actions: Runx2 activity and osteogenesis are stimu-
lated by HES1 [49], but repressed by Hey1/2, and HES6 
promotes neurogenesis, opposing HES1-mediated repression 
of neuron-specific genes. Despite ample evidence suggesting 
different roles for individual Notch receptors and their target 
genes, very little data is available matching individual recep-
tors to specific HES genes expression profiles. 
  Atypical Notch ligands contain IgC2 and fibronectin do-
mains instead of EGF-like repeats and induce a different set 
of genes by binding to different transcription regulators, the 
Deltex family of transcriptional repressors. These are mostly 
involved in nervous system gene expression and develop-
ment. Both canonical and atypical Notch ligands generate the 
same NICD fragments, which then go on to initiate divergent 
transcription mechanisms through CSL and Deltex, respec-
tively. Canonical Notch ligands inhibit Deltex-dependent 
gene expression, thus inhibiting neuronal differentiation and 
promoting cell proliferation through the CSL/HES pathway 
(Fig. (3)). 
NOTCH INVOLVEMENT IN CARDIOVASCULAR 
DEVELOPMENT AND PATHOLOGY  
  Components of the Notch pathway have a broad devel-
opmental role, being involved in the development of the car-
diovascular system but also in embryonic dorso-ventral pat-
terning, neurogenesis, somite and limb development, myo-
genesis and hematopoiesis through direct cell-cell contact. A 
typical result of Notch action is lateral inhibition [50], by 
which an increase in Notch receptor activity and expression 
in one cell decreases receptor expression and increases 
ligand expression in adjacent cells. Thus, a matrix of identi-
cal cells (for example stem cells) starts to diverge when one 
cell responds faster than its neighbors to an external signal 
that activates the Notch pathway. This mechanism also helps 
a cell establish its position relative to other cells and main-
tain tissue architecture.  
  Transgenic mouse models have linked several Notch 
pathway components to vascular system development, in-
cluding Jagged1, Notch1, Notch2, Notch4 and presenilin 
(reviewed in [51]). Mice deficient for these proteins die dur-
ing embryonic development and display severe vascular ab-
normalities, especially Notch1/Notch4 double nulls. The Notch Signaling in Cardiovascular Disease and Calcification  Current Cardiology Reviews, 2008, Vol. 4, No. 3    153 
pattern of Notch ligand and receptor expression during de-
velopment, with some members being restricted to either 
endothelial or vascular smooth muscle cells, may constitute a 
blueprint for angiogenesis (reviewed in [52]). For example, 
the endothelial expression of Jagged1 is required for smooth 
muscle development [53], while Notch1, Notch4 and Dll4 
expression, initially present in the embryo in all blood ves-
sels, become restricted to arteries by day E13, suggesting a 
role for Notch in arterial/ venous specification. At the same 
developmental stage, Notch2 expression becomes absent in 
the aorta but is still present in the pulmonary artery. Notch2 
KO embryos die by day E11.5 due to extensive hemorrhage, 
similarly to Jag1 loss-of-function phenotype. The overlap of 
Jag1 and Notch2 functions is also confirmed by underlying 
mutations in Alagille syndrome (see below).  
  The epithelial-mesenchymal transition, mentioned as a 
potential source of mesenchymal stem cells in the adult vas-
culature and cardiac valves, may occur as a result of Notch 
activation by Jag1, which represses the activation of Wnt 
pathway [54]. Preferential expression of Jagged1 in the en-
dothelial cells of injured blood vessels induces high levels of 
Notch receptors in neighboring smooth muscle cells (Fig. 
(1)) and reduces contact inhibition [55] and cell adhesion 
through a reduction in cadherin levels [56]. This suggests 
that Jagged1 may be involved in the de-differentiation of 
vascular cells and the cellular proliferation phase characteris-
tic for atherosclerosis. The balance between various Notch 
ligands may also regulate the osteogenic process: both Jag1 
and DLL1 enhance BMP2-mediated osteogenic differentia-
tion [57]. In contrast, Dlk1, the inhibitory ligand of Notch 
receptors, is highly expressed in proliferating stem cells and 
inhibits their full differentiation into osteoblasts and adipo-
cytes [58].  
  A number of human genetic disorders resulting from mu-
tations in Notch signaling have demonstrated the implication 
of Notch in the development and maintenance of the cardio-
vascular system. For example the Alagille syndrome is an 
autosomal dominant disorder associated with mutations or 
deletions of Jag1 gene or, in less than 1% of cases, with 
Notch2 mutations. Clinical symptoms are variable but typi-
cally include congenital heart defects, cholestasis, butterfly 
vertebrae and skeletal and facial abnormalities. The cardio-
vascular problems are amplified by frequent kidney abnor-
malities. In mouse models however, both Jag1 and Notch2 
heterozygous mutations are necessary to reproduce the hu-
man Alagille phenotype [51]. The Allagille syndrome is of-
ten accompanied by tetralogy of Fallot symptoms, which 
include ventricular septal defects and pulmonary stenosis 
associated with calcified pulmonary valve. It is interesting to 
note that the skeletal, facial and vertebral abnormalities of 
the Alagille syndrome correlate with arterial calcification, 
suggesting that Jag1 and Notch2 may also play a role in os-
teoblast and bone development. A phenotype similar to the 
Alagille syndrome and Jagged1/Notch2 mice is present in 
mice homozygous for Notch target Hey2 deletion, implying 
the existence of transcriptional specificity for individual 
Notch receptors. 
  CADASIL (cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leukoencephalopathy), a com-
mon form of stroke, is induced by Notch3 mutations that 
prevent its glycosylation and internalization [59, 60] and 
result in the build up of granular material in VSMC mem-
brane, loss of intercellular adhesion and contact, and apopto-
sis. This induces the gradual degradation of the vascular 
wall, impairs blood flow through the cerebral microvascula-
ture and generates blood leaks into surrounding tissue that 
result in recurrent strokes, loss of cognitive functions and 
death [61].  
  Finally, the strongest connection to date between Notch 
signaling and cardiovascular calcification was made by iden-
tifying inactivating Notch1 mutations in 2 families with a 
multi-generation history of bicuspid aortic valve and aortic 
valve calcification [44]. Wild-type Notch1 normally inhibits 
calcification by inducing the expression of its target genes 
Hey1 and Hey2, which interact with and repress the activity 
of Runx2/Cbfa1. Inactivating Notch1 mutations result in 
reduced Hey1/Hey2 expression, allowing the progression of 
Runx2-mediated calcification (Fig (1)).  
INFLAMMATORY SIGNALS AND NOTCH  
  A review on the role of Notch signaling in cardiovascular 
calcification cannot be complete without analyzing the role 
of Notch in macrophages, which trigger the inflammatory 
response and subsequent plaque formation in atherosclerosis 
and valve calcification (Fig. (1)). Juxtacrine communication 
between macrophages appears to be regulated by increased 
DLL4 and Notch3 expression and DLL4/ Notch binding, 
which induces a pro-inflammatory response and macrophage 
activation and proliferation [62]. Notch lateral inhibition 
mechanism could be extrapolated to a similar juxtacrine sig-
naling between activated macrophages and VSMC or valvu-
lar myofibroblasts, inducing a phenotype change in the latter. 
For example, a proliferative signal could be initiated in 
VSMC or myofibroblasts by activating Notch signaling, 
while having an opposite effect in endothelial cells, where 
DLL4 and Notch1 inhibit cell proliferation and angiogenic 
sprouting [63]. 
  In addition to juxtacrine signaling, inflammatory cytoki-
nes released by macrophages, such as IL-1B, IL-6 or TNFal-
pha can also regulate Notch signaling over a longer distance 
(Fig. (1)). Notch and TNFalpha/ NFkappaB pathways coop-
erate in several ways to induce cell proliferation (reviewed in 
[64]). NFkappaB can activate the Notch pathway by induc-
ing Jagged1 expression [65], whereas IkappaB can repress 
Hes1 transcription by binding to its promoter [66] and also 
regulates the cytoplasmic shuttling of transcriptional re-
pressor CSL which transduces Notch signals. In turn, Notch 
up-regulates NFkappaB and IkappaB transcription by se-
questering transcriptional repressor CSL [67, 68]. NFkappaB 
targets IL-1 and IL-6 are known regulators of bone develop-
ment and remodeling. Although they have been mostly 
thought to stimulate osteoclast proliferation, they are also 
strongly expressed in osteoblasts, especially in immature, 
proliferating osteoblasts and recently it has been shown that 
IL-6 enhances the osteoblastic differentiation of mesenchy-
mal stem cells [69].  
  Another paracrine molecule released by activated macro-
phages is nitric oxide (NO, Fig. (1)). Moderate NO quantities 
are normally released with a vasodilatatory role by endothe-154    Current Cardiology Reviews, 2008, Vol. 4, No. 3  Rusanescu et al. 
lial cells lining the vascular wall, but the larger amounts gen-
erated by activated macrophages can be a key factor in the 
mechanism of atherosclerosis [70]. NO can oxidize LDL, 
stimulate platelet aggregation and also induce osteoblast 
proliferation and differentiation [71]. In fact the roles of NO 
in mechanotransduction and bone remodeling, in cooperation 
with integrins and extracellular matrix proteins, have been 
well established (reviewed in [72]). NO and the reactive 
oxygen species it generates are also likely to have a dramatic 
impact on Notch receptors and ligands by disrupting some of 
the disulfide bonds that shape the tridimensional structure of 
their EGF repeats and modify their glycosylation. This in 
turn will impact on Notch receptor binding affinity to its 
ligands and other signaling molecules. Therefore the role of 
NO in osteoblast differentiation may be mediated in part by 
its modulation of Notch signaling.  
CONCLUSION 
  The increased risk of mortality and morbidity associated 
with cardiovascular calcification has lead to the design of 
new therapeutic strategies to prevent and even reverse this 
process. For example, in the case of statins, although recent 
clinical trials have failed to show a reduction in advanced 
calcific aortic stenosis, a growing body of research indicates 
that early use of statins may have therapeutic advantages in 
preventing cardiovascular calcification.  
   A large number of recent publications confirm what was 
until recently just a hypothesis: that arterial and valve calci-
fications are active inflammatory diseases triggered by pro-
atherogenic factors [9, 12, 73]. The molecular connections 
between macrophage signaling and the calcification process 
in arterial walls or valve leaflets are quite numerous and 
greatly exceed the number of publications reviewed in this 
article. An essential aspect of cardiovascular calcification is 
the multipotency of cells that are induced by inflammatory 
signals to proliferate and differentiate into osteoblast precur-
sors. Notch signaling pathway is involved in this process at 
multiple levels: it receives input from inflammatory mole-
cules that induce Notch-mediated cell signaling, it regulates 
cell proliferation and controls the differentiation of various 
cellular lineages including osteoblasts. Notch may have a 
dual role in osteoblast differentiation: contributes to inflam-
matory signals and stimulates early proliferation of immature 
osteoblasts, but also inhibits terminal osteoblastic differentia-
tion by repressing Runx2/Cbfa1 [74]. The combined effect of 
these opposing signals may depend on the stage of cellular 
differentiation, on specific Notch receptors and ligands that 
are involved, and on additional signaling pathways. Much 
progress has been made in recent years in uncovering new 
connections between Notch pathway members, other path-
ways and osteoblast physiology and the large amount of new 
information underlines the complexity of this process and the 
necessity of establishing a rigorous time-dependent sequence 
of events [75].  
  Despite the complexity of cardiovascular calcification, 
rapid progress has been made over the past few years in un-
derstanding its intricacies and the pathways and signaling 
mechanisms of molecules involved. This generates the ex-
pectation that, besides preventive measures currently avail-
able such as non-specific anti-inflammatory medication and 
life-style changes, a new generation of mechanism-specific 
drugs, which can target genetic risk factors and actually re-
verse atheromatous plaques and calcification, will become 
available in the near future.  
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